Caribou CEO On The Evolution Of CAR-T Treatment

25 Apr 2023

Rachel Haurwitz, president and CEO of CRISPR-focused biotech Caribou, sat down with In Vivo to reflect on the thrill of the early days of CRISPR technology, Caribou’s second-generation approach, and the benefits of being a CEO with no prior corporate leadership experience.

Caribou Biosciences Is Developing The Next Generation Of CAR-T Therapies • Source: Shutterstock

Rachel Haurwitz has been making waves in the biotech world since her days as PhD student. As a researcher in the lab of Jennifer Doudna—who later went on to win a Nobel Prize for her work on CRISPR-Cas systems—Haurwitz was there for the early days of the promising technology.

At the age of 27, she made a sharp turn away from academia into the C-suite at Caribou Biosciences,...